Folgen
Sara Lonardi
Sara Lonardi
Istituto Oncologico Veneto IOV-IRCCS, Padova, Italia
Bestätigte E-Mail-Adresse bei iov.veneto.it
Titel
Zitiert von
Zitiert von
Jahr
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo …
CS Fuchs, J Tomasek, CJ Yong, F Dumitru, R Passalacqua, C Goswami, ...
The Lancet 383 (9911), 31-39, 2014
20552014
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
MJ Overman, R McDermott, JL Leach, S Lonardi, HJ Lenz, MA Morse, ...
The lancet oncology 18 (9), 1182-1191, 2017
18232017
Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer
MJ Overman, S Lonardi, KYM Wong, HJ Lenz, F Gelsomino, M Aglietta, ...
13102018
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer
F Loupakis, C Cremolini, G Masi, S Lonardi, V Zagonel, L Salvatore, ...
New England Journal of Medicine 371 (17), 1609-1618, 2014
9722014
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular …
C Cremolini, F Loupakis, C Antoniotti, C Lupi, E Sensi, S Lonardi, S Mezi, ...
The Lancet Oncology 16 (13), 1306-1315, 2015
8962015
Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial
C Aschele, L Cionini, S Lonardi, C Pinto, S Cordio, G Rosati, S Artale, ...
Journal of clinical oncology 29 (20), 2773-2780, 2011
8652011
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with …
J Tabernero, T Yoshino, AL Cohn, R Obermannova, G Bodoky, ...
The Lancet Oncology 16 (5), 499-508, 2015
8012015
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
S Kopetz, A Grothey, R Yaeger, E Van Cutsem, J Desai, T Yoshino, ...
New England Journal of Medicine 381 (17), 1632-1643, 2019
7762019
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of …
A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, S Lonardi, ...
The Lancet Oncology 17 (6), 738-746, 2016
7262016
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial
LC Taieb J1, Tabernero J2, Mini E3, Subtil F4, Folprecht G5, Van Laethem JL6 ...
LANCET ONCOLOGY 15, 862-73, 2014
2662014
Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
E Franceschi, G Cavallo, S Lonardi, E Magrini, A Tosoni, D Grosso, ...
British journal of cancer 96 (7), 1047-1051, 2007
2162007
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
F Loupakis, C Cremolini, L Salvatore, G Masi, E Sensi, M Schirripa, ...
European journal of cancer 50 (1), 57-63, 2014
2132014
Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical …
C Cremolini, D Rossini, E Dell’Aquila, S Lonardi, E Conca, M Del Re, ...
JAMA oncology 5 (3), 343-350, 2019
2112019
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
E Valtorta, C Martino, A Sartore-Bianchi, F Penaullt-Llorca, G Viale, ...
Modern Pathology 28 (11), 1481-1491, 2015
1972015
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis
C Cremolini, M Di Bartolomeo, A Amatu, C Antoniotti, R Moretto, ...
Annals of oncology 26 (10), 2092-2097, 2015
1832015
A phase I–II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer
C Aschele, ML Friso, S Pucciarelli, S Lonardi, L Sartor, G Fabris, ...
Annals of oncology 16 (7), 1140-1146, 2005
1732005
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results …
C Cremolini, F Loupakis, C Antoniotti, S Lonardi, G Masi, L Salvatore, ...
Annals of oncology 26 (6), 1188-1194, 2015
1592015
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with …
C Cremolini, C Antoniotti, D Rossini, S Lonardi, F Loupakis, F Pietrantonio, ...
The Lancet Oncology 21 (4), 497-507, 2020
1532020
Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal CancerHeterogeneity of Acquired Resistance to Anti-EGFRs
F Pietrantonio, C Vernieri, G Siravegna, A Mennitto, R Berenato, ...
Clinical cancer research 23 (10), 2414-2422, 2017
1472017
Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients
R Velasco, J Bruna, C Briani, AA Argyriou, G Cavaletti, P Alberti, B Frigeni, ...
Journal of Neurology, Neurosurgery & Psychiatry 85 (4), 392-398, 2014
1472014
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20